Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Different phenotypes in dermatomyositis associated with anti-MDA5 antibody

(2020) Yves Allenbach et al.   NEUROLOGY

Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease

(2019) Zhiwei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy with High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti‐Melanoma Differentiation‐Associated Gene 5‐Positive Dermatomyositis

(2019) Hideaki Tsuji et al.   Arthritis & Rheumatology

OUP accepted manuscript

(2018)   RHEUMATOLOGY

A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation

(2018) Antonio Gregorio Dias Junior et al.   TRENDS IN MICROBIOLOGY

Serum neopterin as well as ferritin, soluble interleukin 2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody positive dermatomyositis

(2018) Aki Nishioka et al.   Modern Rheumatology

Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis

(2017) Ju Li et al.   JOURNAL OF DERMATOLOGY

Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease

(2014) Takahisa Gono et al.   RHEUMATOLOGY

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

(2012) Javier Carbajo-Lozoya et al.   VIRUS RESEARCH

HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody

(2011) Kiminobu Tanizawa et al.   RESPIRATORY MEDICINE